Gillian Bates, currently co-director of the Huntington’s Disease Research Centre and professor of Neurogenetics at University College London, is at the forefront of the study of the genetic and molecular causes underlying Huntigton’s Disease.
Previously Head of the Division of Genetics and Molecular Medicine at King’s College London, Professor Gillian Bate’s interests comprise the study of this disease pathogenesis and respective validation of therapeutic targets. Her recognized and well-known work made her one of the biggest authorities on the study of this devastating disease that affects movements skills and cognitive abilities. Gillian Bates is also a member of the select Council of the Royal Society. In a revolutionizing and mesmerizing way, Professor Bates has altered the paradigm of study of neurodegenerative diseases.
Robert D. Hare is Emeritus Professor of Psychology, University of British Columbia, where he has taught and conducted research for more than 40 years, and President of Darkstone Research Group Ltd. He was a pioneer in the empirical study of psychopathy, and has devoted most of his academic career to the investigation of the construct, its nature, assessment, and implications for mental health and criminal justice. He is the author of several books and more than two hundred chapters and scientific articles on psychopathy, and is the developer of the Psychopathy Checklist-Revised (PCL-R), the international standard for the clinical/forensic assessment of psychopathy. He and his colleagues were among the first to conduct systematic research on the neurobiology of psychopathy using structural and functional MRI.
He has consulted with the behavioral science divisions of several international criminal justice organizations, including the FBI, the RCMP, and the Italian Carabienari, and is a member of the Dutch Scientific Council of the Expertise Center for Forensic Psychiatry.
Among his many honors and awards are The American Psychiatric Association’s Issac Ray Award for Outstanding Contributions to Forensic Psychiatry and Psychiatric Jurisprudence; the D. O. Hebb Award for Distinguished Contributions to Psychology as a Science; and the Bruno Klopfer Award for Outstanding, Long-term Professional Contribution to the Field of Personality Assessment. The Society for the Scientific Study of Psychopathy made him the first recipient of an award named after him, The R.D. Hare Lifetime Achievement Award. He is a member of the Order of Canada.
Levi J. Hargrove, PhD, P.Eng, received his MScE and PhD in Electrical Engineering from the University of New Brunswick (2005, 2008). He is currently the Associate Director of Center for Bionic Medicine at the Shirley Ryan AbilityLab, formerly the Rehabilitation Institute of Chicago (RIC), and an Associate Professor in the Departments of Physical Medicine & Rehabilitation and the McCormick School of Engineering at Northwestern University. His research interests include signal processing, pattern recognition, and myoelectric control of powered prostheses. A major goal of his research is to develop clinically realizable myoelectric control systems that can be made available to persons with limb loss in the near future. In 2012, Dr. Hargrove co-founded Coapt, a company to commercialize control algorithms for prosthetics and orthotics. His research addresses all levels of amputation and has been published in the Journal of the American Medical Association and the New England Journal of Medicine and multiple patents. Key projects include the development of advanced and adaptive control systems for prosthetic legs, improving control of robotic hand prostheses, and intramuscular EMG signal processing.
Professor James Fallon is an American neuroscientist, Professor of Psychiatry and a specialist in human behavior. He is also Professor Emeritus of Anatomy and Neurobiology at the Irvine School of Medicine at the University of California.
Throughout his career, he has contributed to the development of several topics in the field of neurosciences, namely through the discovery of TGF-α and EGF. He was the first to demonstrate the use of growth factors for stimulation of stem cells in damaged adult brain, on a large scale. He also contributed to research in the fields of Schizophrenia, Parkinson’s Disease and Alzheimer’s Disease.
He discovered during one of the investigations that the magnetic resonances of his brain had activated circuits compatible with the patterns of psychopathic individuals, which he himself had studied and established. He has since proclaimed himself a pro-social psychopath. His unique perspective on this topic will unequivocally enrich the session.
Professor Ivan Đikić is Director of the Institute of Biochemistry II at the Goethe University of Frankfurt, having developed relevant advances in the study of cellular signalling mecanisms.
Ivan Đikić has brilliantly demonstrated how ubiquitin, a small ubiquous protein, contributes to regulate a series of pathways in the inner cell. Author to numerous publications in international high impact scientific journals, has dramatically altered how Science sees this molecule. From proteossomal activity to selective autophagyregulation, his undoubtely relevant research is of great scientific interest. Thus, it is no wonder he has received more than a dozen prizes and awards such as The Order of Duke Branimir in 2010 and the 2013 Gottfried Wilhelm Leibniz Prize.
This speaker is brought to you with the support of EMBO.
Grégoire Courtine is an Associate Professor at the Federal Institute of Technology of Lausanne (EPFL). In 2012, he accepted from the International Paraplegic Foundation the Chair in Spinal Cord Repair at EPFL’s Centre of Neuroprosthetics and the Brain Mind Institute.
Initially, his study focused on the understanding of the neural networks of locomotion and neuronal plasticity and the potential of effective rehabilitation of locomotion. Grégoire Courtine became internationally famous when he succeeded to recover mobility in paraplegic rats, using cerebral implants.
In November 2016, Courtine announced on Nature that he had executed this deed in monkeys, a feat that was received with great repercussion from worldwide media.
Having received numerous prizes, such as the 2007 UCLA Chancellor’s Award and the Schellenberg Prize in 2009, Grégoire Courtine’s work is indeed impressive and the clinic potencial of his accomplishments in the treatment of paralisis are really remarkable.
Rodrigo Quiroga is director of the Centre for Systems Neuroscience in University of Leicester, in the United Kingdom. He has remarkably contributed for the development of this field of study. Professor Quiroga, also Head of Bioengineering, has indeed made extraordinary advances regarding memory and visual perception.
By discovering the Jennifer Aniston neurons, brain cells pivotal to the formation of new memories, Professor Quiroga revolutionized the paradigm of study of this scientific area. This discovery may also explain phenomena not fully understood such as the creation of episodic memory or even the flow of conscience.
Currently, Rodrigo Quian Quiroga is studying how is information stored in the human brain, through the analysis of individual neuron electric profiles, by taking advantage of intracranial electrodes implanted in epileptic patients.
Therefore, his groundbreaking work is of utmost interest and is already allowing the development of novel Neuroprosthetic techniques with true therapeutic potential.
Dr. Nicholas Lydon has extensive experience in drug discovery and development and is one of the three recipients of the 2009 Lasker Award for the discovery of Imatinib and its applications in the treatment of Chronic Myeloid Leukemia. His work broke new ground in cancer therapy and radically changed the prognosis of CML patients.
Dr. Lydon is a co-founder and Director of AnaptysBio (San Diego, USA) and of BluePrint Medicines (Cambridge, USA). He previously served as Vice President at Amgen and was also the CEO and founder of Kinetix Pharmaceuticals, a biotechnology company focused on the discovery and development of selective protein kinase inhibitors.
Dr. Lydon also worked at CIBA-GEIGY (now Novartis), in Basel, Switzerland, where he was responsible for the tyrosine protein kinase inhibitor program, including the discovery and preclinical development of Imatinib (Gleevec®). He has been awarded the 2009 Lasker Award and the 2012 Japan Prize for his groundbreaking work on this molecule.
This speaker is brought to you with the support of ASPIC.